Opendata, web and dolomites

RapidEx SIGNED

Validation of a point-of-care H-FABP test for a rapid exclusion of Acute Myocardial Infarction in patients with cardiac complaints.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RapidEx project word cloud

Explore the words cloud of the RapidEx project. It provides you a very rough idea of what is the project "RapidEx" about.

protein    unnecessary    fabpulous    occurrence    trials    majority    sme    gross    fatty    pain    netherlandsbelgium    proportion    core    trt    blood    intended    ce    drop    physician    performing    point    consequently    guidelines    home    addressable    acute    2018    outcomes    helps    reimbursement    phased    market    tests    marked    patients    select    biomarker       infarction    health    rapid    advantages    device    myocardial    fabp    decrease    care    professionals    population    spun    80    thereby    ami    form    confidence    proprietary    sent    heart    inspection    consult    complaints    maastricht    clinical    sustainable    primary    healthcare    least    rule    diluted    binding    uk    diagnosis    acid    admissions    there    true    plan    economically    technologies    referrals    validate    university    hcp    nw    18    hospital    price    revenue    emergency    mln    ruling    plasma    innovative    amounts    insurers    adoption    chest    suspected    improvement    leads    aids    2008    request    diagnosed    alone    pressing    basis    hcps    medical       offers    introduction    company    saving    margin    medico    reduce    ultra    preparation   

Project "RapidEx" data sheet

The following table provides information about the project.

Coordinator
FABPULOUS BV 

Organization address
address: OXFORDLAAN 55
city: MAASTRICHT
postcode: 6229 EV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://fabpulous.com/
 Total cost 1˙633˙750 €
 EC max contribution 1˙633˙750 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2017-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FABPULOUS BV NL (MAASTRICHT) coordinator 1˙633˙750.00

Map

 Project objective

There is a pressing need for improvement of the diagnosis of acute myocardial infarction (AMI) for healthcare professionals (HCP). 1–1,5% of the population consult a physician each year with chest pain complaints. While the majority (60–80%) of these patients are sent to a hospital for further inspection, eventually AMI is diagnosed in only 8–18% of these cases. Consequently, a rapid, objective test that helps to better select patients suspected of AMI by HCPs would reduce the number of unnecessary hospital referrals and admissions, thereby saving costs and contributing to a more sustainable healthcare.

FABPulous (SME) is a medical device company spun out of Maastricht University in 2008. The core of the company is its innovative proprietary technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages over current technologies in point-of-care and home testing.

The CE-marked H-FABP True Rapid Test (H-FABP TRT) developed by FABPulous aids the HCP in ruling out AMI with a very high level of confidence. It is based on the heart-type fatty acid binding protein (H-FABP), which can be used as biomarker for AMI. With H-FABP TRT a physician is able to rule out the occurrence of an AMI for a large proportion of patients suspected of AMI. It is intended for use in both primary and emergency care.

In this project FABPulous seeks to medico-economically validate H-FABP TRT in primary (NetherlandsBelgium) and emergency care (UK) by performing two clinical trials. Outcomes of these studies lead to adoption of H-FABP TRT in medical guidelines and form the basis of a request for reimbursement towards health insurers. In this project FABPulous will improve the production process as well in order to decrease the cost price to €5 per test.

The addressable market in NW Europe alone amounts to at least 2 mln tests. The phased introduction plan leads to €8.6 mln revenue with a gross margin of €6.5 mln in 2018.

 Deliverables

List of deliverables.
Clinical study protocol emergency care trial Documents, reports 2019-04-15 17:08:30

Take a look to the deliverables list in detail:  detailed list of RapidEx deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPIDEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RAPIDEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More